ProCE Banner Activity

Phase III KEYNOTE-426: Updated Analysis of First-line Pembrolizumab Plus Axitinib vs Sunitinib in Advanced RCC

Slideset Download
Conference Coverage
After nearly 2 years of follow-up, pembrolizumab plus axitinib provides durable improvements in OS and PFS as compared with sunitinib in treatment-naive patients with advanced RCC.

Released: June 02, 2020

Expiration: June 01, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono